Abstract
Background The goal of the present work was to examine risk factors for mortality in a 1,387 COVID+ patients admitted to a hospital in Suffolk County, NY.
Methods Data were collated by the hospital epidemiological service for patients admitted from 3/7/2020-9/1/2020. Time until final discharge or death was the outcome. Cox proportional hazards models were used to estimate time until death among admitted patients.
Findings In total, 99.06% of cases had resolved leading to 1,179 discharges and 211 deaths. Length of stay was significantly longer in those who died as compared to those who did not p=0.007). Of patients who had been discharged (n=1,179), 54 were readmitted and 9 subsequently died. Multivariable-adjusted Cox proportional hazards regression revealed that in addition to older age, male sex, and heart failure that a history of premorbid depression was a risk factors for COVI-19 mortality (HR = 2.64 [1.54-4.54] P<0.001), and that this association remained after adjusting for age and for neuropsychiatric conditions as well as medical comorbidities including cardiovascular disease and pulmonary conditions. Sex-stratified analyses revealed that associations between mortality and depression was strongest in males (aHR = 4.45 [2.04-9.72], P<0.001), and that the association between heart failure and mortality was strongest in participants aged <65 years old (aHR = 30.50 [9.17-101.48], P<0.001).
Interpretation While an increasing number of studies have identified a number of comorbid medical conditions and age of patient as risk factors for mortality in COVID+ patients, this study reports that history of depression is a risk factor for COVID mortality.
Funding No funding was received for this study.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for the completion of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Stony Brook IRB Reviewed and approved the study (#1586703).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Streamlining analysis.
Data Availability
Data include private health information and are not available to outside users, but have been archived to COVID data-sharing websites including TriNetX.
